Key Drivers
- Strong Cash Flow
- Weak Profitability
- High Intangibles
AIAI Summary
Revvity's improving Diagnostics growth, cash conversion, and software/AI strategy support a credible recovery, but at roughly 60x earnings after a major rally, investors should wait for broader life-sciences acceleration and sustained margin expansion before underwriting the premium valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •Weak Profitability
- •High Intangibles
RVTY has strong liquidity and cash flow, but weak profitability, high intangible-asset exposure, and elevated valuation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Strong monthly gain
- •Near resistance
- •Pullback risk
RVTY gained 16% over the last month and remains bullish above $140, but near-$147 resistance and elevated momentum favor waiting for a confirmed breakout or pullback.
Sharp advance from the
Sentiment & News
Key News Insights:
- •Raised 2026 outlook
- •Strategic cell acquisition
- •Valuation risks persist
Revvity's upgraded outlook, strong stock momentum, and planned Human Cell Design acquisition support a constructive long-term view, though elevated valuation and estimate-revision risks warrant caution.
Positive catalysts may support further upside, but premium valuation could increase volatility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings